Pfizer Battles 2nd FCA Suit Over Antifungal Drug Promotions

Law360, New York (June 13, 2012, 8:33 PM EDT) -- A Massachusetts federal judge Monday unsealed an ex-Pfizer Inc. manager's False Claims Act suit accusing the drug giant of a long-running and illegal campaign to promote off-label use of antifungal drugs, echoing similar allegations in a complaint last year.

Paul Worsfold, a former district manager at Pfizer, says his ex-employer recklessly and unnecessarily endangered patient health by encouraging unapproved uses of Vfend and Eraxis.

Alleged offenses include promoting off-label treatment in children under 12 and in individuals with neutropenia, a blood disorder commonly caused by cancer...
To view the full article, register now.